Oral Dosage Form New Animal Drugs; Neomycin Sulfate Oral Solution
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Med-Pharmex, Inc. The ANADA provides for the oral use of neomycin sulfate solution for the treatment and control of colibacillosis in cattle, swine, sheep, and goats.
Table of Contents Back to Top
- FOR FURTHER INFORMATION CONTACT:
- SUPPLEMENTARY INFORMATION:
- List of Subjects in 21 CFR Part 520
- PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
DATES: Back to Top
This rule is effective September 5, 2000.
FOR FURTHER INFORMATION CONTACT: Back to Top
Dianne T. McRae, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0212.
SUPPLEMENTARY INFORMATION: Back to Top
Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767-1861, filed ANADA 200-289 that provides for the oral use of neomycin sulfate solution for the treatment and control of colibacillosis in cattle, swine, sheep, and goats. Med-Pharmex's ANADA 200-289 NEORAL® (neomycin sulfate) Oral Solution is approved as a generic copy of Pharmacia Upjohn's NADA 011-315 NEOMIX® 325 Soluble Powder. The application is approved as of July 3, 2000, and the regulations in 21 CFR 520.1485 are amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.
In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS Back to Top
1.The authority citation for 21 CFR part 520 continues to read as follows:
§ 520.1485 [Amended]
2.Section 520.1485 Neomycin sulfate oral solution is amended in paragraph (b) by adding in numerical order after “000009,” the entry “051259,”.
Dated: August 23, 2000.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 00-22571 Filed 9-1-00; 8:45 am]
BILLING CODE 4160-01-F